New pill combined with hormone therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new pill (TT00420) taken with standard hormone therapy for prostate cancer that has spread and is no longer responding to initial hormone treatment. The goal is to see if the combination can help slow the cancer's growth and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older with advanced prostate cancer.
- Your cancer has spread to at least two bones or to soft tissue (shown on a scan).
- You have been on continuous hormone therapy (medical or surgical) for at least 90 days and your testosterone level is very low.
- Your cancer has gotten worse while on a newer hormone therapy (like abiraterone or an AR inhibitor) for at least one month.
- You have not had more than one type of chemotherapy for prostate cancer in the castration-resistant phase.
- You have not been treated with a tyrosine kinase inhibitor (TKI) drug before.
- You are generally able to perform daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called tinengotinib combined with standard treatments for men with advanced prostate cancer that has stopped responding to abiraterone or enzalutamide. The goal is to see if the combination can help control the cancer.
This trial tests a new pill for advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The pill targets a specific gene change in the cancer, so part of the trial includes genetic testing of your tumor.
This trial tests a new oral drug, XNW5004, for men with advanced prostate cancer that has spread or stopped responding to standard treatments. It may be given alone or with other therapies like abiraterone, enzalutamide, or chemotherapy, and aims to find better ways to control the disease.
This trial tests a new combination treatment for men with advanced prostate cancer that has stopped responding to usual hormone therapy. It compares high-dose testosterone followed by darolutamide to standard care, and may help control the cancer longer.
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
Hear when a new Prostate Cancer (CRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.